JPRN-UMIN000004792招募中2 期
Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation - Pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation
Dept of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan0 个研究点目标入组 20 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Negative cytomegalovirus antibodies of both of donors and recipients T-cell depleted or CD34-positive cell selected transplantation Gut GVHD (>=stage 2) HLA more than 2 locus disparity
研究者
相似试验
招募中
不适用
Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial)Patients with locally advanced pancreatic cancer (BR-A or UR-LA) scheduled for pancreatic resectionJPRN-UMIN000046618Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama45
已完成
2 期
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000030457Fujita Health University School30
进行中（未招募）
不适用
Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab - R-GVHDChronic graft versus host diseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2009-016898-14-FRCHU de Nantes
进行中（未招募）
1 期
Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic TrioxideFirst line treatment of Chronic Graft versus Host Disease in patients having received a first allogeneic stem cell transplantation for a hematological diseaseEUCTR2016-002358-18-FRMedsenic24
进行中（未招募）
1 期
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30